Magnetorotational neutron star kicks

Autor: Kondratyev, Ilya A., Moiseenko, Sergey G., Bisnovatyi-Kogan, Gennady S.

Publikováno v: Physical Review D, 110, 8, 083025 (2024)

High velocity neutron stars, observed as rapidly moving radio-pulsars, are believed to gain high linear velocities -- kicks -- in aspherical supernova explosions. The mechanism of the kick formation is probably connected with anisotropic neutrino fla

Externí odkaz: http://arxiv.org/abs/2410.09521

Pedagogical Support for Professional Development of Officers of the Ministry of Internal Affairs of Russia

Autor: Kupavtsev Timofei Sergeevich, Moiseenko Andrei Andreevich, Struganov Sergei Mikhaylovich, Kosolapov Alexei Dmitrievich, Mironkina Oksana Nikolaevna

Publikováno v: SHS Web of Conferences, Vol 108, p 05007 (2021)

The system of professional training of officers of the Ministry of Internal Affairs of Russia is meant to ensure the competence of a specialist and his high professional readiness for implementing the law-enforcement functions by means of a deep theo

Externí odkaz: https://doaj.org/article/4cefd5e56af14b2c8c90cd51c538d85e

Wave propagation and transformation in the frame of magnetohydrodynamics with a vortex electric field

Autor: Bisnovatyi-Kogan, G. S., Kondratyev, I. A., Moiseenko, S. G.

Bright transient objects in different wave bands have been discovered in recent years. To explain these short (from ms to s), and very powerful events different models, galactic and extragalactic, have been considered. One of popular model is based o

Externí odkaz: http://arxiv.org/abs/2306.17724

A phase III study to access the safety and efficacy of prolgolimab 250 mg fixed dose administered every 3 weeks versus prolgolimab 1 mg/kg every 2 weeks in patients with metastatic melanoma (FLAT)

Autor: Lev Demidov, Galina Kharkevich, Natalia Petenko, Vladimir Moiseenko, Svetlana Protsenko, Tatiana Semiglazova, Anastasia Zimina, Nadezhda Kovalenko, Natalia Fadeeva, Dmitry Kirtbaya, Igor Belogortsev, Denis Tantsyrev, Svetlana Odintsova, Alfia Nesterova, Karina Vorontsova, Yulia Makarycheva, Yulia Linkova, Arina Zinkina-Orikhan, Anna Siliutina, Irina Sorokina, Daria Liaptseva, Vladimir Chistyakov, Anton Lutsky

Publikováno v: Frontiers in Oncology, Vol 14 (2024)

BackgroundProlgolimab is the first Russian PD-1 inhibitor approved for the first-line treatment of unresectable or metastatic melanoma and advanced non-small cell lung cancer. It was approved in two weight-based regimens of 1 mg/kg Q2W and 3 mg/kg Q3

Externí odkaz: https://doaj.org/article/f9e274f24e4c449f852c192658eb49c8

Final data on the efficacy of the FORA study (FOrteca Real practice Assessment): a multicenter prospective observational study on the real-world efficacy of prolgolimab in patients with metastatic melanoma in Russia

Autor: Kristina V. Orlova, Mikhail Iu. Fedyanin, Konstantin E. Simanenkov, Aleksandr S. Dergunov, Petr R. Goldshmidt, Aleksandra F. Saydullaeva, Darya V. Bogacheva, Marina A. Yavorskaya, Artur Z. Azanov, Alexander A. Fedenko, Larisa V. Bolotina, Tatyana I. Deshkina, Kseniya G. Babina, Ekaterina A. Kuzevanova, Liudmila G. Zhukova, Polina S. Feoktistova, Natalya I. Polshina, Ekaterina V. Peganova, Valentina E. Shikina, Maksim M. Sobolev, Oleg V. Mironov, Vera A. Vaschenko, Mariya M. Ershova, Agniya O. Mezhueva, Svetlana A. Orlova, Denis A. Tantsyrev, Darya K. Taskina, Antonina A. Teterich, Elena V. Karabina, Yuliya V. Kostalanova, Marina V. Bogacheva, Natalia V. Zhukova, Rashida V. Orlova, Maksim V. Zinkevich, Aleksandr I. Kazmin, Mikhail V. Volkonskiy, Liya M. Voronkova, Anastasiya S. Karpova, Mikhail L. Maleyko, Mariya N. Gorshenina, Elena I. Kryuchkova, Fedor V. Moiseenko, Yuliya I. Murzina, Shamil I. Musin, Andrey N. Ogloblin, Mariya S. Perminova, Regina A. Dumbrava, Sergey A. Emelyanov, Svetlana A. Protsenko, Alexander V. Sultanbaev, Anna V. Tarasova, Elena B. Shakhnovich, Marina V. Demchenkova, Yuliya A. Lozovskaya, Khedi S. Musaeva, Elena M. Pavlova, Roman A. Skotnikov, Vera V. Chernova, Angelina S. Chichkanova, Adina M. Akhmatova, Marina A. Zafirova, Andrey A. Mischenko, Elena N. Ovsienko, Viktoriya A. Petrukhnenko, Oksana A. Syusyukaylova, Yana A. Tyugina, Elena A. Shumilkina, Daniil L. Stroyakovskiy, Aleksandr N. Yurchenkov, Pavel L. Baldin, Anastasiya S. Belova, Olga V. Diduk, Elena A. Konovalova, Lyudmila N. Lebedeva, Yaroslav A. Li, Viktoriya V. Mashtapa, Yana A. Mironenkova, Kristina V. Narovenkova, Olga A. Pavlikova, Elvira L. Parsadanova, Irina S. Pimonova, Anna A. Ruzhnikova, Irina D. Sivunova, Ekaterina P. Soloveva, Maksim I. Sosnin, Kh. Toita Temirsultanova, Makhabbat Zh. Tyulegenova, Aleksandra V. Khodkevich, Nadezhda R. Shakurova, Sureya N. Efendieva, Karine L. Avagimyan, Ekaterina Р. Anokhina, Mariya I. Antoshkina, Stanislav M. Borzyanitsa, Samir K. Dzhentemirov, Marina V. Dmitrochenko, Alla V. Zheleznyak, Yuliya V. Komoza, Aleksandr S. Kopanev, Tatyana I. Kornienko, Margarita A. Krasilnikova, Darya A. Lukhmanova, Natalya S. Mazur, Polina M. Markina, Zhargal S. Mitapov, Svetlana N. Osodoeva, Irina A. Prokopenko, Irina M. Radyukova, Madina S. Ramazanova, Alfiya R. Safarova, Mariya A. Safronova, Khalimat M. Khabrieva, Natalya S. Tsygankova, Kseniya V. Chermakova, Tatyana A. Chirkova, Igor V. Samoylenko, Valeria V. Nazarova, Angelina E. Akhmetyanova, Lev V. Demidov

Publikováno v: Современная онкология, Vol 26, Iss 1, Pp 20-34 (2024)

Background. Prior to the introduction of new agents — immune checkpoint inhibitors — for inoperable and/or metastatic melanoma (IMM), chemotherapy outcomes were generally poor. The median (Me) overall survival (OS) in IMM was no more than 6-9 mon

Externí odkaz: https://doaj.org/article/fff40d04a39d498ba7ec6262154c7020